Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

Imatinib has marked antileukemic activity in advanced Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), but secondary resistance develops rapidly, reflecting the limitations of single-agent therapy. Experimental data suggest that interferon- α (IFN- α ) enhances the antileuke...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2003-10, Vol.17 (10), p.1919-1924
Hauptverfasser:	Wassmann, B, Scheuring, U, Pfeifer, H, Binckebanck, A, Käbisch, A, Lübbert, M, Leimer, L, Gschaidmeier, H, Hoelzer, D, Ottmann, O G
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia Acute lymphocytic leukemia Aged Anticancer properties Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzamides Biological and medical sciences Cancer Research Central nervous system Chemotherapy Chemotherapy, Combination Chromosomes Critical Care Medicine Dosage and administration Drug therapy Female Health aspects Hematologic and hematopoietic diseases Hematology Humans Imatinib Imatinib Mesylate Immunotherapy Inhibitor drugs Intensive Interferon Interferon alpha Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Internal Medicine Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphatic leukemia Male Medical sciences Medicine Medicine & Public Health Middle Aged Minimal residual disease Oncology Patients Pharmacology. Drug treatments Philadelphia chromosome Piperazines - administration & dosage Piperazines - adverse effects Prophylaxis Pyrimidines - administration & dosage Pyrimidines - adverse effects Remission spotlight Stem cell transplantation Stem cells Targeted cancer therapy Time Factors Toxicity Transplantation Treatment Outcome α-Interferon
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!